Predictive Factor of Local Recurrence After Balloon-occluded TACE with Miriplatin (MPT) in Hepatocellular Carcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Jul 23

PMID 25047920

Citations 13

Authors

Toru Ishikawa

Satoshi Abe

Ryousuke Inoue

Tomoyuki Sugano

Yuhsuke Watanabe

Akito Iwanaga

Keiichi Seki

Terasu Honma

Takeo Nemoto

Keiko Takeda

Toshiaki Yoshida

Affiliations

Soon will be listed here.

Abstract

Background: Miriplatin (MPT) is a novel platinum complex used in TACE that shows promise for the treatment of hepatocellular carcinoma (HCC). However, rapid washout has been reported in some cases. Therefore, various methods of administration with MPT have been attempted to increase its therapeutic efficacy. One hopeful method is balloon-occluded TACE (B-TACE), but the therapeutic efficacy of B-TACE with MPT has not been evaluated.

Aim: To investigate the treatment outcomes and factors involved in local recurrence after B-TACE with MPT in HCC.

Methods: This study included 51 patients (55 nodules) with HCC lesions equal or less than 5 cm in diameter who underwent B-TACE with MPT between January 2012 and June 2013. Local recurrence after B-TACE with MPT and factors associated with local recurrence were evaluated.

Results: The overall local recurrence rate was 11.1% at 6 months and 26.2% at 12 months. The local recurrence rate did differ significantly depending on CT values immediately after B-TACE with MPT. Multivariate analysis also showed that the CT value after B-TACE with MPT was the only factor related to local recurrence after B-TACE.

Conclusions: B-TACE with MPT achieves relatively good local control of HCC. The plain CT value immediately after B-TACE with MPT is a predictive factor for local recurrence. In patients with unsatisfactory CT values, locoregional therapy or additional treatment is required.

Citing Articles

Comparison of Local Recurrence Between LEN-TACE and TACE for Hepatocellular Carcinoma According to Lipiodol Accumulation.

Ishikawa T, Sato R, Jimbo R, Kobayashi Y, Sato T, Iwanaga A Cancer Diagn Progn. 2024; 4(5):611-616.

PMID: 39238622 PMC: 11372692. DOI: 10.21873/cdp.10371.

Efficacy and features of balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: a narrative review.

Ishikawa T Transl Gastroenterol Hepatol. 2024; 9:48.

PMID: 39091662 PMC: 11292099. DOI: 10.21037/tgh-23-117.

Microballoon Interventions for Liver Tumors: Review of Literature and Future Perspectives.

Lucatelli P, Rocco B, Ciaglia S, Damato E, Mosconi C, Argiro R J Clin Med. 2022; 11(18).

PMID: 36142980 PMC: 9505296. DOI: 10.3390/jcm11185334.

Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching.

Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A Liver Cancer. 2021; 10(5):522-534.

PMID: 34721513 PMC: 8529335. DOI: 10.1159/000516613.

Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis.

Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A Cardiovasc Intervent Radiol. 2021; 44(7):1048-1059.

PMID: 33709273 PMC: 8189964. DOI: 10.1007/s00270-021-02805-5.

References

Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M . Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol. 2010; 194(3):830-7. DOI: 10.2214/AJR.09.3308. View

Maeda M, Uchida N, Sasaki T . Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res. 1986; 77(6):523-5. View

Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S . A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer. 1987; 60(6):1194-203. DOI: 10.1002/1097-0142(19870915)60:6<1194::aid-cncr2820600607>3.0.co;2-t. View

Aoyama K, Tsukishiro T, Okada K, Tsuchida T, Aiba N, Nambu S . Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinoma. Cancer Chemother Pharmacol. 1992; 31 Suppl:S55-9. DOI: 10.1007/BF00687106. View

Ohnishi K, Tsuchiya S, Nakayama T, Hiyama Y, Iwama S, Goto N . Arterial chemoembolization of hepatocellular carcinoma with mitomycin C microcapsules. Radiology. 1984; 152(1):51-5. DOI: 10.1148/radiology.152.1.6203138. View

Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T . Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci. 2008; 100(1):189-94. PMC: 11159647. DOI: 10.1111/j.1349-7006.2008.01010.x. View

Okita K . Management of hepatocellular carcinoma in Japan. J Gastroenterol. 2006; 41(2):100-6. DOI: 10.1007/s00535-005-1763-0. View

Miyayama S, Yamashiro M, Shibata Y, Hashimoto M, Yoshida M, Tsuji K . Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol. 2012; 30(3):263-70. DOI: 10.1007/s11604-011-0043-6. View

Tommasini M, Colombo M, Sangiovanni A, Orefice S, Bignami P, Doci R . Intrahepatic doxorubicin in unresectable hepatocellular carcinoma. The unfavorable role of cirrhosis. Am J Clin Oncol. 1986; 9(1):8-11. DOI: 10.1097/00000421-198602000-00002. View

10.

Irie T, Kuramochi M, Takahashi N . Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol. 2012; 36(3):706-13. DOI: 10.1007/s00270-012-0476-z. View

11.

Colleoni M, Gaion F, Liessi G, Mastropasqua G, Nelli P . Arterial chemoembolization with epirubicin in unresectable hepatocellular-carcinoma in cirrhosis. Oncol Rep. 2011; 1(6):1171-5. DOI: 10.3892/or.1.6.1171. View

12.

Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N . Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2008; 64(3):473-83. PMC: 2691803. DOI: 10.1007/s00280-008-0895-3. View

13.

Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M . Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987; 163(2):345-51. DOI: 10.1148/radiology.163.2.3031724. View

14.

Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H . Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993; 188(1):79-83. DOI: 10.1148/radiology.188.1.8390073. View

15.

Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S . Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983; 148(2):397-401. DOI: 10.1148/radiology.148.2.6306721. View

16.

Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y . Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res. 2012; 42(6):523-42. DOI: 10.1111/j.1872-034X.2012.00981.x. View

17.

Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y . Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs. 2004; 22(2):169-76. DOI: 10.1023/B:DRUG.0000011793.72775.d1. View

18.

Tohma T, Cho A, Okazumi S, Makino H, Shuto K, Mochiduki R . Communicating arcade between the right and left hepatic arteries: evaluation with CT and angiography during temporary balloon occlusion of the right or left hepatic artery. Radiology. 2005; 237(1):361-5. DOI: 10.1148/radiol.2371040919. View

19.

Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T . Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. Cancer. 2011; 117(17):4018-25. DOI: 10.1002/cncr.25989. View

20.

Taylor-Robinson S, Foster G, Arora S, Hargreaves S, Thomas H . Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997; 350(9085):1142-3. DOI: 10.1016/S0140-6736(05)63789-0. View